Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Open Access Gateway

Pathobiological Implications of MUC16/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type

Higashi M.a · Yamada N.a · Yokoyama S.a · Kitamoto S.a · Tabata K.a · Koriyama C.b · Batra S.c · Yonezawa S.a

Author affiliations

Departments of aHuman Pathology, Field of Oncology, and bEpidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; cDepartments of Biochemistry and Molecular Biology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebr., USA

Corresponding Author

Michiyo Higashi, MD, PhD

Department of Human Pathology, Field of Oncology

Kagoshima University Graduate School of Medical and Dental Sciences

8-35-1 Sakuragaoka, Kagoshima 890-8544 (Japan)

Tel. +81 99 275 5270, E-Mail east@m2.kufm.kagoshima-u.ac.jp

Related Articles for ""

Pathobiology 2012;79:101–106

Do you have an account?

Login Information

Contact Information

By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.

I have read the Karger Terms and Conditions and agree.


Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion: The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.

© 2012 S. Karger AG, Basel


  1. Nakanuma Y, Curado MP, Franceschi S, Gores G, Paradis V, Sripa B, Tsui WMS, Wee A: Intrahepatic cholangiocarcinoma; in Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC, 2010, pp 217–219.
  2. Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS, Sato E: Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999;30:1347–1355.
  3. Aljiffry M, Walsh MJ, Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 2009;15:4240–4262.
  4. Kokudo N, Makuuchi M: Extent of resection and outcome after curative resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2002;11:969–983.
  5. Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45–60.
  6. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aikou T, Tanaka S, Irimura T, Kim YS, Sato E: Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 1998;4:2605–2614.
  7. Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M: Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 2008;8:3329–3341.
  8. Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T, Osako M, Takao S, Batra SK, Aikou T, Imai K, Yonezawa S: MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 2005;58:845–852.
  9. Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, Imai K, Yonezawa S: MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 2004;39:220–229.
  10. Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, Imai K, Yonezawa S: MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res 2006;12:4257–4264.
  11. O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L: The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348–366.
  12. O’Brien TJ, Beard JB, Underwood LJ, Shigemasa K: The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002;23:154–169.
  13. Yin BW, Lloyd KO: Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371–27375.
  14. Cioffi M, Fratta M, Gazzerro P, Di Finizio B, Tucci A, Mollinari AM: OVCA (CA125) second generation: technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease. Tumori 1997;83:594–598.
  15. Higashi M, Goto M, Saitou M, Shimizu T, Rousseau K, Batra SK, Yonezawa S: Immunohistochemical study of mucin expression in periampullary adenomyoma. J Hepatobiliary Pancreat Sci 2010;17:275–283.
  16. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ: Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol 1999;52:283–290.
  17. McCluggage WG: Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol 2000;53:327–334.
  18. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766–3772.
  19. Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Miyazaki M: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002;89:1525–1531.
  20. Hardardottir H, Parmley TH 2nd, Quirk JG Jr, Sanders MM, Miller FC, O’Brien TJ: Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol 1990;163:1925–1931.
  21. Kobayashi H, Ohi H, Moniwa N, Shinohara H, Terao T: Characterization of CA 125 antigen identified by monoclonal antibodies that recognize different epitopes. Clin Biochem 1993;26:391–397.
  22. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS: Mesothelin-MUC16 binding is a high affinity, N-glycan-dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5:50.
  23. Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, Makuuchi M: A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001;92:2374–2383.
  24. Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Konishi M, Kinoshita T, Miyagawa S, Kawasaki S: Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000;127:498–505.
  25. Aishima S, Asayama Y, Taguchi K, Sugimachi K, Shirabe K, Shimada M, Tsuneyoshi M: The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma. Mod Pathol 2002;15:1181–1190.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 12, 2011
Accepted: November 11, 2011
Published online: January 27, 2012
Issue release date: February 2012

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 3

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.